Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


Purpose:

This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV). This study will evaluate the safety and tolerability of the combination of these drugs when they are used in the treatment of metastatic colorectal cancer. This is a pilot clinical trial which will be studying the reactions of the patient's body and tumor to the experimental treatment described above. The purpose of this study is to find out what kind of side effects this experimental treatment causes and see how often these side effects occur.


Criteria:

Inclusion Criteria: - Patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis. - Patients may have received adjuvant chemotherapy and/or one regimen of chemotherapy for metastatic disease. Patients must not have been previously treated with the combination of irinotecan/5-FU/LV. - Patients must be past their 18th birthday at the time of enrollment. - Patients must have a performance status of 0-2 at the time of registration. - Patients must have a life expectancy of > 3 months. - If patients have undergone recent surgery, they must have fully recovered from the effects of that surgery prior to enrollment. - Patients must have a pretreatment leukocyte count > 3,000/l, absolute neutrophil count >1500/l, hemoglobin >8 mg/dl, and platelet count of > 150,000/l within 2 weeks of enrollment. - Patients must have adequate renal function, as documented by a serum creatinine < 2.0 mg/dl, and have adequate hepatic function, as documented by a serum bilirubin < 1.1 mg/dl within 2 weeks of enrollment. Exclusion Criteria: - Patients must not have active infection. - Patients must have no serious medical or psychiatric illness, other than that treated by this study, which would limit the ability of the patient to receive protocol therapy or give informed consent. - Patients must not have a history of active malignancy, other than that treated by this study, within the 12 months preceding enrollment. - Pregnant or lactating women may not participate. Women of reproductive age must undergo a serum pregnancy test within 14 days of enrollment. Men and women of reproductive potential must use an effective contraceptive method during the study. - There must be no plans for the patient to receive concomitant antineoplastic therapy while on this protocol. All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.


Study is Available At:


Original ID:

UMCC 0075


NCT ID:

NCT00176774


Secondary ID:


Study Acronym:


Brief Title:

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma


Official Title:

A Pilot Trial of Irinotecan, 5-Fluorouracil, and Leucovorin Combined With the Anti-Angiogenesis Agent Tetrathiomolybdate in Metastatic Colorectal Carcinoma (UMCC 0075)


Overall Status:

Completed


Study Phase:

Phase 2


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

University of Michigan Cancer Center


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Non-Randomized, Intervention Model:


Number of Arms:

1


Number of Groups:

0


Total Enrollment:

24


Enrollment Type:

Actual


Overall Contact Information

Official Name:Mark Zalupski, M.D.
Principal Investigator
University of Michigan Cancer Center

Study Dates

Start Date:February 2001
Completion Date:April 2004
Completion Type:Actual
Primary Completion Date:February 2004
Primary Completion Type:Actual
Verification Date:February 2012
Last Changed Date:February 5, 2012
First Received Date:September 12, 2005

Study Outcomes

Outcome Type:Secondary Outcome
Measure:To determine the success rate of TM leading to target levels of copper depletion in patients treated concurrently with chemotherapy
Time Frame:12 months
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:To determine the tolerability and toxicity of tetrathiomolybdate (TM) in combination with irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer.
Time Frame:12 months
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:To evaluate the progression free survival in patients with metastatic colorectal cancer when treated with this regimen.
Time Frame:24 months
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Toxicity
Time Frame:12 months
Safety Issues:True
Outcome Type:Primary Outcome
Measure:To determine the tolerability and toxicity of tetrathiomolybdate (TM) in combination with irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer.
Time Frame:12 months
Safety Issues:True
Outcome Type:Primary Outcome
Measure:OBJECTIVES
Time Frame:12 months
Safety Issues:False

Study Interventions

Intervention Type:Drug
Name:Irinotecan
Description:Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
Intervention Type:Drug
Name:5-Fluorouracil
Description:Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
Intervention Type:Drug
Name:Leucovorin
Description:Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
Intervention Type:Drug
Name:Tetrathiomolybdate
Description:one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:University of Michigan Cancer Center

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.